Jobevne / Abevmy / Krabeva
Bevacizumab biosimilar developed by Biocon Biologics, development code Bmab-100. Reference product Avastin.
Brands by market: Jobevne (USA); Abevmy (EU, UAE); Krabeva (India) · Commercial partner or holder: Biocon Biologics
FDAApr 2025approved
EMAApr 2021authorised
CDSCOMay 2017permitted
EDEFeb 2022registered
Status by market
FDA
United States · Jobevne
US Food and Drug AdministrationApprovedBrand
Jobevne
Holder or applicant
Biocon Biologics Inc.
Pathway
351(k)
Approved
Apr 2025
Application or permission
761175
Licence type
351(k) biosimilar, not interchangeable
Presentations
100 mg/4 mL, 400 mg/16 mL
Source
S001, S016
EMA
European Union · Abevmy
European Medicines Agency and European CommissionApprovedBrand
Abevmy
Holder or applicant
Biosimilar Collaborations Ireland Limited
Pathway
Centralised (Article 10(4))
Approved
Apr 2021
Application or permission
EMEA/H/C/005327
Presentations
see SmPC
Source
S017
CDSCO
India · Krabeva
Central Drugs Standard Control OrganisationApprovedBrand
Krabeva
Holder or applicant
Biocon Limited
Pathway
Similar Biologic, manufacture and marketing permission
Approved
May 2017
Application or permission
MF-90/2017; BULK-91/2017
Indications as licensed
Colorectal, NSCLC, renal, ovarian, cervical cancer, glioblastoma
Presentations
100 mg/4 mL and 400 mg/16 mL
Source
S014
EDE
United Arab Emirates · Abevmy
Emirates Drug EstablishmentRegisteredBrand
Abevmy
Holder or applicant
Biocon Biologics Limited, India · UAE supplier Lunatus Drug Store LLC
Pathway
Registered medical product
Registered
Feb 2022
Presentations
400 mg vial (Feb 2022); 100 mg vial (Jun 2022)
Source
S018
Chronology
- CDSCOMay 2017CDSCO permission granted as Krabeva
- EMAApr 2021Authorised by the European Commission as Abevmy
- EDEFeb 2022Registered in the UAE as Abevmy
- FDAApr 2025Approved by FDA as Jobevne
Sources
S001FDA, Biosimilar Product Information (approved biosimilars table) Primary (regulator)S016FDA Purple Book, monthly data downloads January to August 2026 Primary (regulator)S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)S018UAE Emirates Drug Establishment, registered medical product directory Primary (regulator)
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.